SPCG-5
High-dose Polyestradiol Phosphate versus Total Androgen Blockade
Donec sed odio dui. Donec ullamcorper nulla non metus auctor fringilla. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit tempus porttitor. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum.
5 publications
Publications of the SPCG-5 trial
Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival
Johansen JS, Brasso K, Iversen P, Teisner B, Garnero P, Price PA, Christensen IJ
Clin Cancer Res. 2007
Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: Results from the scandinavian prostate cancer group study 5
Jønler M, Nielsen OS, Groenvold M, Hedlund PO, Damber L, Hedelin H, Waldén M, & the Scandinavian Prostate Cancer Group Study 5 Study Group
Scand J Urol Nephrol. 2005
Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer. Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette Å, Rasmussen F, Salo J, Vaage S, Varenhorst E and the SPCG-5 Study Group
Scand J Urol Nephrol. 2002
Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate
Spetz A-C, Hammar M, Lindberg B, Spångberg A, Varenhorst E and the Scandinavian Prostatic Cancer Group-5 Trial Study
J Urol. 2001
Parenteral Estrogen versus Total Androgen Ablation in the Treatment of Advanced Prostate Carcinoma: Effects on Overall Survival and Cardiovascular Mortality
Hedlund PO, Henriksson P
Urology. 2000